For the analysis by tumor subtype, hormone receptor positivity was assessed in each trial under the available criteria at that moment, and the lack of information on HER2 in the GEICAM/9805 trial substantially decreases the statistical power of the analyses. This evidence concerns the gene ERBB2 and neoplasm.